Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Alexion Pharmaceuticals Q4 Profit Rises - Quick Facts

RELATED NEWS
Trade ALXN now with 

Alexion Pharmaceuticals Inc. (ALXN: Quote) reported fourth-quarter GAAP net income of $81.0 million, or $0.40 per share up from $48.2 million, or $0.25 per share in the year ago quarter.

Non-GAAP net income for the quarter was $122.3 million, or $0.60 per share, compared to non-GAAP net income of $80.5 million, or $0.41 per share last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.53 per share for the quarter. Analysts' estimates typically exclude special items.

Net product sales of Soliris (eculizumab) was $320.5 million, compared to $227.6 million for the same period in 2011. Twenty analysts had consensus revenue estimate of $316.49 million for the quarter.

The year-on-year increase in net product sales of 41 percent reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS) commencing Soliris treatment.

In 2013, worldwide net product sales are expected to be within a range of $1.490 billion to $1.505 billion. On a non-GAAP basis, R&D expenses are expected to be in the range of $285 to $295 million, and SG&A expenses in the range of $425 to $435 million.. Based on a forecast of approximately 205 million diluted shares outstanding, Alexion is providing guidance of $2.82 to $2.92 for non-GAAP earnings per share for the year.

Analysts expect the company to report earnings of $2.81 per share on revenues of $1.49 billion for fiscal 2013.

Register
To receive FREE breaking news email alerts for Alexion Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.